Intravenous ipamorelin in people

Healthy volunteers receiving intravenous ipamorelin

The human pharmacokinetic study characterized intravenous ipamorelin in healthy male volunteers. Its terminal half-life was approximately 2 hours. The growth-hormone response took the form of a single discrete pulse, peaking at about 40 minutes after dosing.

Those clocks deserve separate attention, I think. One describes the decline in the peptide's plasma concentration; the other locates the peak of the hormone response. Neither clock measures muscle gain, sleep quality or the practical recovery of someone after surgery. They characterize a particular exposure and its hormone response.

These measurements come from intravenous administration of the parent peptide in healthy men.

Median meal-tolerance times

The randomized proof-of-concept trial involved 114 adults undergoing open or laparoscopic bowel resection. Median time to the first tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo; p=0.15. The trial missed its primary endpoint.

The direction of the medians favoured ipamorelin. For me, those medians offer weaker encouragement than a successful endpoint test would have. A missed endpoint leaves room for uncertainty about the size of an effect. More persuasive clinical results would be necessary before I described the compound as a useful way to restore eating after bowel surgery.

The short safety window

In that perioperative trial, treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm and 94.8% of the placebo arm. The report identified no ipamorelin-specific safety signal in the short perioperative window. Those percentages describe events appearing during treatment; they do not assign every event to the drug.

The broader peptide-therapy review emphasizes scarce rigorous human safety data. For confidence to grow, I need evidence for the population, route and duration being proposed. A brief surgical trial and an acute volunteer experiment give a limited kind of reassurance.

A useful return journey

The oral analogue experiments in dogs answer a chemical-development question. The intravenous human study answers a question about exposure and hormone release. The bowel-surgery trial asks about recovery of eating. This untidy itinerary suits me; each stop has a particular purpose.

The reading list brings those destinations together. The research becomes more interesting when the destination has a name.